Aurobindo Pharma has exclusive rights to develop and commercialise UB-612 in India and to UNICEF, and non-exclusive rights in other select emerging markets. The company can supply up to 480 million doses of UB-612 for India and other countries.Aurobindo Pharma faces delay in getting its COVID-19 vaccine plan rolling
Aurobindo Pharma has exclusive rights to develop and commercialise UB-612 in India and to UNICEF, and non-exclusive rights in other select emerging markets. The company can supply up to 480 million doses of UB-612 for India and other countries.
Subscribe to:
Post Comments (Atom)
-
Huawei faces international scrutiny over its ties with the Chinese government and suspicion that Beijing could use Huawei#39;s technology f...
-
The NCLT#39;s Ahmedabad bench has directed the RP to include GAIL in the list of creditors for both the companies.
-
"The (latest) investment will be used to grow the mobile esports format and establish presence in select overseas markets through its ...
No comments:
Post a Comment